ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Long-Acting GH Deficiency Treatments to Boost Market Growth from 2017
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 22484" data-attributes="member: 3"><p>According to Key Opinion Leaders (KOLs) interviewed by GlobalData, patient compliance with daily growth hormone drugs has been a long-standing issue in the GHD treatment landscape, and it remains the greatest unmet need.</p><p>As a consequence, pharmaceutical companies are focusing heavily on developing easier delivery options for patients, leading to therapies that can be administered weekly or bi-weekly. Indeed, nine of the 12 drugs currently in development for GHD are long-acting growth hormone biobetters.</p><p>Many patients who currently refuse to take their daily growth hormone injections are expected to opt for the long-acting drugs once they become available, which will begin to increase the drug treatment rate.</p><p></p><p><a href="http://admin.dddmag.com/news/2015/08/long-acting-gh-deficiency-treatments-boost-market-growth-2017?et_cid=4736021&et_rid=449166332&location=top" target="_blank">http://admin.dddmag.com/news/2015/08/long-acting-gh-deficiency-treatments-boost-market-growth-2017?et_cid=4736021&et_rid=449166332&location=top</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 22484, member: 3"] According to Key Opinion Leaders (KOLs) interviewed by GlobalData, patient compliance with daily growth hormone drugs has been a long-standing issue in the GHD treatment landscape, and it remains the greatest unmet need. As a consequence, pharmaceutical companies are focusing heavily on developing easier delivery options for patients, leading to therapies that can be administered weekly or bi-weekly. Indeed, nine of the 12 drugs currently in development for GHD are long-acting growth hormone biobetters. Many patients who currently refuse to take their daily growth hormone injections are expected to opt for the long-acting drugs once they become available, which will begin to increase the drug treatment rate. [URL]http://admin.dddmag.com/news/2015/08/long-acting-gh-deficiency-treatments-boost-market-growth-2017?et_cid=4736021&et_rid=449166332&location=top[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Long-Acting GH Deficiency Treatments to Boost Market Growth from 2017
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top